{
    "clinical_study": {
        "@rank": "63647", 
        "arm_group": [
            {
                "arm_group_label": "YH1885L 33.3 mg", 
                "arm_group_type": "Experimental", 
                "description": "TID, Subject takes it for 4 week."
            }, 
            {
                "arm_group_label": "YH1885L 50mg", 
                "arm_group_type": "Experimental", 
                "description": "BID, Subject takes it for 4 week."
            }, 
            {
                "arm_group_label": "YH1885L 66.6 mg", 
                "arm_group_type": "Experimental", 
                "description": "TID, Subject takes it for 4 week."
            }, 
            {
                "arm_group_label": "YH1885L 100mg", 
                "arm_group_type": "Experimental", 
                "description": "BID, Subject takes it for 4 week."
            }, 
            {
                "arm_group_label": "Esomeprazole 20mg", 
                "arm_group_type": "Active Comparator", 
                "description": "QD, Subject takes it for 4 week."
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to\n      investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive\n      reflux disease(NERD)"
        }, 
        "brief_title": "Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-erosive Reflux Disease", 
        "condition_browse": {
            "mesh_term": "Gastroesophageal Reflux"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects who signed written informed consent form\n\n          -  more than 20 yr subject\n\n          -  subjects who agree the use of medically accepted birth control during trial\n\n          -  grade N, M by EGD test\n\n          -  subject who experience 2 day out of 1 week during recent 1 month\n\n          -  subject who experience 2 day out of 1 week during run-in period\n\n        Exclusion Criteria:\n\n          -  subjects who can write the diary by himself, herself\n\n          -  pregnant woman, breastfeeding woman\n\n          -  allgeric or intolerabiliy to revaprazan or esomeprazole\n\n          -  feeling of heavy stomach, distention\n\n          -  surgery history in stomach or esophagus\n\n          -  active medical history of stomach, esophagus area\n\n          -  other system disorder which can disturb this trial\n\n          -  Hep B, C virus, HIV carrier or patients\n\n          -  past history of malignant tumor\n\n          -  any psychiatric past or current history\n\n          -  abnormal lab test\n\n          -  abnormal ecg test\n\n          -  zollinger-ellison disease\n\n          -  current or past history of substance, drug abuse\n\n          -  subject who should regulary takes medication which can disturb this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750437", 
            "org_study_id": "YH1885L-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "YH1885L 33.3 mg", 
                    "YH1885L 50mg", 
                    "YH1885L 66.6 mg", 
                    "YH1885L 100mg"
                ], 
                "intervention_name": "YH1885L(Revaprazan)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Esomeprazole 20mg", 
                "intervention_name": "Esomeprazole 20mg", 
                "intervention_type": "Drug", 
                "other_name": "Nexium"
            }, 
            {
                "arm_group_label": [
                    "YH1885L 50mg", 
                    "YH1885L 100mg", 
                    "Esomeprazole 20mg"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Omeprazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "NERD", 
        "lastchanged_date": "July 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "DongA university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyungbook University hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chungnam university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Catholic Incheon hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Jeonbuk University hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Catholic yeouido sungmo hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Konkuk unversity hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyunghee university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "5", 
        "official_title": "Randomized, Double-blind, Active-controlled, Multi-center Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)", 
        "other_outcome": {
            "measure": "Comparison of H.pylori(+),(-) subjects about primay and seconday outcome", 
            "safety_issue": "No", 
            "time_frame": "4 week"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "'complete recovery' means subjects never experience heartburn or acid regurgitation during last 1 week.", 
            "measure": "the rate of subject who had 'complete recovery' of symptom after 4 week administration", 
            "safety_issue": "No", 
            "time_frame": "4 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "'Appropriate recovery' means subjects experience heartburn or acid regurgitation only 1 or less during last 1 week.", 
                "measure": "the rate of subject who had 'appropriate recovery' of symptom after 4 week administration", 
                "safety_issue": "No", 
                "time_frame": "4 week"
            }, 
            {
                "measure": "the rate of subject who had 'complete recovery' after 1 week, 2 week, 3 week IP administraion", 
                "safety_issue": "No", 
                "time_frame": "3 week"
            }, 
            {
                "measure": "the rate of subject who had 'appropriate recovery' after 1 week, 2 week, 3 week IP administraion", 
                "safety_issue": "No", 
                "time_frame": "3 week"
            }, 
            {
                "description": "Symptoms means \"Heartburn or Acid regurgitation\"", 
                "measure": "the number of night symptom-free day after IP administration", 
                "safety_issue": "No", 
                "time_frame": "1 week, 2 week, 3 week, 4 week"
            }, 
            {
                "measure": "the rate of subjects who have reduced average symptom score(more than 1) comparing to baseline score", 
                "safety_issue": "No", 
                "time_frame": "1 week, 2 week, 3 week, 4 week"
            }, 
            {
                "measure": "Evalution of Clinical Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "4 week"
            }, 
            {
                "measure": "Evaluation of Patient Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "4 week"
            }, 
            {
                "measure": "the change of SF-36 Survey score between baseline and completion visit", 
                "safety_issue": "No", 
                "time_frame": "4 week"
            }, 
            {
                "description": "ESS stands for Epworth sleepiness scale.", 
                "measure": "the change of ESS survey score among baseline, 2 week and 4 week", 
                "safety_issue": "No", 
                "time_frame": "2, 4 week"
            }, 
            {
                "description": "AE, Physical exam, 12-lead ECG, Vital signs, laboratory test", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "4 week"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}